LUTATHERA (R) in first line therapy of G2 and G3 GEP-NETs (the NETTER-2 study)

Ferone D, Pavel ME, Kunz P, De Herder W, Santoro P, Wegener A, Broberg P, Ravasi L, Singh S (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

European Journal of Nuclear Medicine and Molecular Imaging Springer Verlag (Germany)

Publisher: SPRINGER

City/Town: NEW YORK

Pages Range: S88-S89

Conference Proceedings Title: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Event location: Barcelona, SPAIN

Authors with CRIS profile

Marianne Ellen Pavel Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Involved external institutions

Advanced Accelerator Applications SA FR France (FR) Stanford University US United States (USA) (US) University of Toronto CA Canada (CA) Ospedale San Martino (IRCCS AOU) IT Italy (IT) Erasmus University Medical Center (MC) NL Netherlands (NL)

How to cite

APA:

Ferone, D., Pavel, M.E., Kunz, P., De Herder, W., Santoro, P., Wegener, A.,... Singh, S. (2019). LUTATHERA (R) in first line therapy of G2 and G3 GEP-NETs (the NETTER-2 study). In EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (pp. S88-S89). Barcelona, SPAIN: NEW YORK: SPRINGER.

MLA:

Ferone, D., et al. "LUTATHERA (R) in first line therapy of G2 and G3 GEP-NETs (the NETTER-2 study)." Proceedings of the 32nd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Barcelona, SPAIN NEW YORK: SPRINGER, 2019. S88-S89.

BibTeX: Download